Jane Street’s Jade Biosciences JBIO Stock Holding History

Jane Street’s Portfolio JBIO Stock Details JBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-483	Closed	-$28.1K	–	9553
2024 Q2	$28.1K	Buy	+483	New	+$320K	﹤0.01%	9014

Other funds holding JBIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Jane Street's JBIO Position: Q2 2025 in Review

Jane Street sold out of Jade Biosciences (JBIO) in Q2 2025, closing a stake of 315 shares — an estimated $27.6K sold.

Jane Street first reported a position in JBIO in Q4 2021 and held it in 7 quarters. The position peaked at $333K in Q1 2024. 75 funds tracked by Wall St. Rank hold JBIO as of Q2 2025.

Jane Street reported no remaining Jade Biosciences position as of Q2 2025 after selling out during the quarter.
Jane Street sold 315 Jade Biosciences shares in Q2 2025, an estimated $27.6K.
Jane Street first reported a position in Jade Biosciences in Q4 2021 and held it in 7 quarters.
Jane Street's Jade Biosciences position peaked at $333K in Q1 2024.
75 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2025.

Based on Jane Street's 13F filing for Q2 2025, filed 14 Aug 2025.